More interestingly, in a study on 33 patients with cardiovascular diseases undergoing open heart surgery aimed to assess the expression of GLP-1R as well as the glucose-dependent insulinotropic polypeptide receptor (GIPR) and the glucagon receptor (GCGR), it was found that human EAT expresses GLP-1R, GIPR, and GCGR at similar levels of mRNA and protein in macrophages and partially in adipocytes [95], suggesting that these G-protein-coupled receptors could be targeted by multi-receptor innovative drugs with cardiometabolic benefits beyond their effects on glucose and body weight [95,96]. The gene discussed is GLP1R; the disease is cardiovascular disorder.